

## **AGENDA**

## MDUK Oxford Neuromuscular Centre Annual Meeting

Wednesday 26<sup>th</sup> March 2025

tical Instituto University 12 Math

			L2, Mathematical Institute, University of Oxford				
08:00	-	08:30	Registration, Tea, & Pastries				
Session 1: Future plans for the MDUK Oxford Neuromuscular Centre							
08:30	-	09:20	Welcome from the Director Prof Matthew Wood, Dept of Paediatrics, University of Oxford Early diagnosis and treatment in DMD Prof Laurent Servais, Dept of Paediatrics, University of Oxford				
Session 2: DMD diagnosis and evaluation – Chair: Prof Dame Kay Davies							
09:20	-	10:40	<ul> <li>Newborn screening for DMD: milestones and remaining challenges</li> <li>Prof Emma Ciafaloni, University of Rochester Medical Center</li> <li>SV95C: Can digital endpoints be the solution for early evaluation of boys with DMD?</li> <li>Damien Eggenspieler, SYSNAV Healthcare</li> <li>Access to treatments: what we should all be thinking about from diagnosis and beyond</li> <li>Emily Reuben, Duchenne UK</li> </ul>				
10:40	-	11:00	Tea & Coffee				
Session 3: DMD therapies – Chair: Prof Laurent Servais							
11:00	-	12:30	<b>Treating the patient with DMD: choices and challenges</b> Prof Richard Finkel, <i>St Jude Children's Research Hospital</i> <b>Industry perspective on early interventional therapies in DMD</b> <u>Panel members</u> : Dr Angela Guerra ( <i>Avidity Biosciences</i> ), Dr Ashish Dugar ( <i>Dyne Therapeutics</i> ), Dr Hayley Parker ( <i>PepGen</i> ), Dr Shabir Hasham ( <i>Santhera Pharmaceuticals</i> ), Dr Rachel Salazar ( <i>Sarepta Therapeutics</i> ), and Dr Alexander Lin ( <i>Wave Life Sciences</i> )				

12:30 - 13:30 Lunch

Session 4: Motor Neurone Disease - Chair: Prof Martin Turner

13:30		Studying pre-symptomatic populations at risk of ALS Dr Alex Thompson, Nuffield Dept of Clinical Neurosciences, University of Oxford
		From pre-clinical models to Experimental Medicine in ALS Prof Kevin Talbot, Nuffield Dept of Clinical Neurosciences, University of Oxford
	- 15:20	Biomarkers of treatment response in antisense oligonucleotide (Tofersen) studies in ALS Dr Carrie Rubel, <i>Biogen</i>
		Creation of de novo cryptic splicing for ALS and FTD precision medicine Prof Pietro Fratta, University College London



15:20 - 15:40 Tea & Coffee

## Session 5: Featured Centre projects - Chair: Dr Sithara Ramdas

15:40 - 1	7:00	<ul> <li>Using immunoassays to unravel the inflammatory neuropathies</li> <li>A/Prof Simon Rinaldi, Nuffield Dept of Clinical Neurosciences, University of Oxford</li> <li>Myasthenia gravis - changes in demographics, features and management over the last decades</li> <li>A/Prof Isabel Leite, Nuffield Dept of Clinical Neurosciences, University of Oxford</li> <li>Expanding the CRISPR toolkit for neuromuscular disease</li> <li>Prof Carlo Rinaldi, Dept of Paediatrics, University of Oxford</li> <li>Wrap-up and closing</li> <li>Dr Sithara Ramdas, Oxford University Hospitals</li> </ul>
17:00 - 1	.8:00	Posters & Drinks Reception

Thank you to our industry sponsors

## SAREPTA THERAPEUTICS

LIFE SCIENCES





۸v

BIOSCIENCES

